GSPE Spacer
The General Hospital Corporation, d/b/a Massachusetts · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a September 11, 2026 substantial-equivalence decision for K260063, the GSPE Spacer from The General Hospital Corporation doing business as Massachusetts General Hospital. The summary describes a single-use knee spacer with femoral and tibial components. The femoral component is available in gentamicin-sulfate-blended UHMWPE or cobalt-chrome alloy; the tibial component uses gentamicin-sulfate-blended UHMWPE. FDA's documents list Class II, regulation 888.3560 and product codes JWH and MBB.
The summary assigns different primary predicates to the two configurations: The Knee Spacer (REMEDY Knee Spacer), K112470, for the All-GSPE Spacer, and the Rx Knee System, K240683, for the CoCr-GSPE Spacer. It lists wear, elution, antibacterial activity, stability and biocompatibility testing, and states that performance results support substantial equivalence. The excerpts do not provide numerical test results. This explanation preserves the configuration-specific predicate relationships without converting the submission's testing conclusion into an independent clinical assessment.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260063
- Regulatory pathway
- 510(k) premarket notification
- Product code
- JWH
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer.
- Product code
- JWH
- FDA device class
- 2
FDA decision timeline
K260063 received
Application receipt date recorded by FDA.
K260063 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JWH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MicroPort Total Knee SystemK263065 | Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Oct 29, 2026 | FDA |
GMK ExtensionK262057 | Medacta International SA | 510(k) clearance | Sep 15, 2026 | FDA |
| Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Sep 10, 2026 | FDA | |
| B-One Ortho, Corp. | 510(k) clearance | Sep 8, 2026 | FDA | |
ATTUNE Revision Knee SystemK262130 | Depuy Orthopaedics, Inc. | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
The General Hospital Corporation, d/b/a Massachusetts
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Somerville, MA
Sources and methodology
- Original FDA record: K260063
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


